<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Pharmaceuticals on FinanClub</title>
    <link>https://finan.club/tags/pharmaceuticals/</link>
    <description>Recent content in Pharmaceuticals on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 23 Mar 2024 09:01:55 +0000</lastBuildDate><atom:link href="https://finan.club/tags/pharmaceuticals/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>CBAY</title>
      <link>https://finan.club/us/cbay/</link>
      <pubDate>Sat, 23 Mar 2024 09:01:55 +0000</pubDate>
      
      <guid>https://finan.club/us/cbay/</guid>
      <description>score:-158
Chances: Gilead Sciences, Inc. has completed the acquisition of CymaBay Therapeutics, Inc. for approximately $4.3 billion, indicating positive returns for CBAY shareholders. Risks: The acquisition may result in changes in CymaBay&amp;rsquo;s product pipeline and research direction, leading to uncertainty for investors. The acceptance of seladelpar NDA for priority review by the U.</description>
    </item>
    
    <item>
      <title>MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Tue, 06 Feb 2024 09:06:04 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:126
Chances: Merck &amp;amp; Co. has demonstrated its commitment to expanding its animal health business through the recent acquisition of Elanco&amp;rsquo;s aqua business. The company&amp;rsquo;s strong earnings report and solid guidance indicate that it is well-positioned to thrive despite potential challenges such as the expiration of its patent on Keytruda.</description>
    </item>
    
    <item>
      <title>OGN</title>
      <link>https://finan.club/us/ogn/</link>
      <pubDate>Wed, 20 Dec 2023 09:03:44 +0000</pubDate>
      
      <guid>https://finan.club/us/ogn/</guid>
      <description>score:21
Chances: Organon&amp;rsquo;s partnership with Sempre Health to improve medication adherence shows a proactive approach to patient care and may lead to increased sales. The company&amp;rsquo;s exclusive distribution of Emgality and RAYVOW in Europe presents a significant opportunity for revenue growth in the region.</description>
    </item>
    
  </channel>
</rss>
